MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Loss of membrane MHC class I protein expression in most of tumor cells in advanced melanomas predicts primary resistance to anti–CTLA-4, but not anti-PD1, treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another study, MHC I downregulation via transcriptional repression was associated with primary resistance to anti-CTLA-4 therapy but not to anti-PD-1 therapy, and the response to anti-PD-1 was more dependent on MHC II expression linked to an IFN-γ-regulated module of genes (97).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [97]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSalmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Cited by
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
Bagaev, A., Kotlov, N., Nomie, K., Svekolkin, V., Gafurov, A., Isaeva, O., Osokin, N., Kozlov, I., Frenkel, F., Gancharova, O., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.014 · Cited by 1,302
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
Liu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0654-5 · Cited by 1,039
Acquired Resistance to Immune Checkpoint Inhibitors
Schoenfeld, A. J., & Hellmann, M. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.017 · Cited by 955
Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875
“Signature scores were calculated for RNA-seq transcriptome profiles of pre-treatment samples from melanoma trial Checkmate 064 (Rodig et al., 2018).”
BackgroundMethodSelf-citationRevisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
Dynamics and specificities of T cells in cancer immunotherapy
Oliveira, G., & Wu, C. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00560-y · Cited by 616
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès-Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 602
Hara, T., Chanoch-Myers, R., Mathewson, N. D., Myskiw, C., Atta, L., Bussema, L., Eichhorn, S. W., Greenwald, A. C., Kinker, G. S., Rodman, C., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.002 · Cited by 593
The dormant cancer cell life cycle
Phan, T. G., & Croucher, P. I. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0263-0 · Cited by 576
The hallmarks of successful anticancer immunotherapy
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575
Self-citationImmunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J., & Guo, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 569
Benci, J. L., Johnson, L. R., Choa, R., Xu, Y., Qiu, J., Zhou, Z., Xu, B., Ye, D., Nathanson, K. L., June, C. H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.019 · Cited by 541
Self-citationTurning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
A single-cell landscape of high-grade serous ovarian cancer
Izar, B., Tirosh, I., Stover, E. H., Wakiro, I., Cuoco, M. S., Alter, I., Rodman, C., Leeson, R., Su, M.-J., Shah, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0926-0 · Cited by 504
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Axelrod, M. L., Cook, R. S., Johnson, D. B., & Balko, J. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3200 · Cited by 490
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 471
Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox
Oh, D. Y., & Fong, L. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.015 · Cited by 467
“A separate examination of two independent phase II clinical trials of checkpoint inhibition in melanoma similarly found that anti-PD-1 responses associated with increased MHC class II expression and IFN-γ signaling prior to treatment (Rodig et al., 2018).”
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
Grasso, C. S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., Champhekar, A., Medina, E., Torrejon, D. Y., Shin, D. S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.005 · Cited by 390
Self-citationSignal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Zhang, M., Hu, S., Min, M., Ni, Y., Lu, Z., Sun, X., Wu, J., Liu, B., Ying, X., & Liu, Y. (2021) · Gut · doi:10.1136/gutjnl-2019-320368 · Cited by 339
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer
Cachot, A., Bilous, M., Liu, Y.-C., Li, X., Saillard, M., Cenerenti, M., Rockinger, G. A., Wyss, T., Guillaume, P., Schmidt, J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe3348 · Cited by 328
Ni, J., Wang, X., Stojanovic, A., Zhang, Q., Wincher, M., Bühler, L., Arnold, A., Correia, M. P., Winkler, M., Koch, P.-S., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.001 · Cited by 324
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
Taylor, B. C., & Balko, J. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844866 · Cited by 298
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
Paulson, K. G., Voillet, V., McAfee, M. S., Hunter, D. S., Wagener, F. D., Perdicchio, M., Valente, W. J., Koelle, S. J., Church, C. D., Vandeven, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06300-3 · Cited by 286
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0812 · Cited by 273
“Nevertheless, the clinical observation in melanoma treated by ICB (13) suggests that a large number of patients can still benefit from this approach.”
BackgroundSelf-citationNK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists
Nicolai, C. J., Wolf, N., Chang, I.-C., Kirn, G., Marcus, A., Ndubaku, C. O., McWhirter, S. M., & Raulet, D. H. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz2738 · Cited by 268
Programming cell pyroptosis with biomimetic nanoparticles for solid tumor immunotherapy
Zhao, P., Wang, M., Chen, M., Chen, Z., Peng, X., Zhou, F., Song, J., & Qu, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120142 · Cited by 263
Cho, J.-W., Hong, M. H., Ha, S.-J., Kim, Y.-J., Cho, B. C., Lee, I., & Kim, H. R. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00493-8 · Cited by 259
Mechanisms of immune activation and regulation: lessons from melanoma
Kalaora, S., Nagler, A., Wargo, J. A., & Samuels, Y. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00442-9 · Cited by 240
The Contribution of Epigenetics to Cancer Immunotherapy
Villanueva, L., Álvarez-Errico, D., & Esteller, M. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.002 · Cited by 235
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
Tian, H., Cao, J., Li, B., Nice, E. C., Mao, H., Zhang, Y., & Huang, C. (2023) · Bone Research · doi:10.1038/s41413-023-00246-z · Cited by 232
Pre-clinical modeling of cutaneous melanoma
Rebecca, V. W., Somasundaram, R., & Herlyn, M. (2020) · Nature Communications · doi:10.1038/s41467-020-15546-9 · Cited by 228
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“Impaired antigen presentation may be a mechanism of resistance to ICB therapy, including HLA heavy chain, light chain B2M, and other antigen presentation components [110, 112, 113].”
BackgroundPembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Olson, D. J., Eroglu, Z., Brockstein, B., Poklepovic, A. S., Bajaj, M., Babu, S., Hallmeyer, S., Velasco, M., Lutzky, J., Higgs, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00079 · Cited by 221
Cancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jerusalem, G., Hubert, P., & Herfs, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 205
Willsmore, Z. N., Coumbe, B. G. T., Crescioli, S., Reci, S., Gupta, A., Harris, R. J., Chenoweth, A., Chauhan, J., Bax, H. J., McCraw, A., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202048747 · Cited by 204
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Hazini, A., Fisher, K., & Seymour, L. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002899 · Cited by 203
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade
Berry, S., Giraldo, N. A., Green, B. F., Cottrell, T. R., Stein, J. E., Engle, E. L., Xu, H., Ogurtsova, A., Roberts, C., Wang, D., et al. (2021) · Science · doi:10.1126/science.aba2609 · Cited by 199
Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts
Kerdidani, D., Aerakis, E., Verrou, K.-M., Angelidis, I., Douka, K., Maniou, M.-A., Stamoulis, P., Goudevenou, K., Prados, A., Tzaferis, C., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210815 · Cited by 196
Landscape of helper and regulatory antitumour CD4+ T cells in melanoma
Oliveira, G., Stromhaug, K., Cieri, N., Iorgulescu, J. B., Klaeger, S., Wolff, J. O., Rachimi, S., Chea, V., Krause, K., Freeman, S. S., et al. (2022) · Nature · doi:10.1038/s41586-022-04682-5 · Cited by 196
Self-citationResistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 191
TGF-β Signaling and Resistance to Cancer Therapy
Zhang, M., Zhang, Y. Y., Chen, Y., Wang, J., Wang, Q., & Lu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.786728 · Cited by 191
Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy
Wang, H., Liu, B., & Wei, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.008 · Cited by 190
CD4+ T cells in antitumor immunity
Montauti, E. I., Oh, D. Y., & Fong, L. H. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.009 · Cited by 185
The advent of immune stimulating CAFs in cancer
Tsoumakidou, M. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00549-7 · Cited by 185
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Dangaj Laniti, D., & Coukos, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00503-z · Cited by 180
Cai, H., Yan, L., Liu, N., Xu, M., & Cai, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109790 · Cited by 175
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Advances and prospects of biomarkers for immune checkpoint inhibitors
Yamaguchi, H., Hsu, J.-M., Sun, L., Wang, S., & Hung, M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101621 · Cited by 168
Mondello, P., Tadros, S., Teater, M., Fontan, L., Chang, A. Y., Jain, N., Yang, H., Singh, S., Ying, H.-Y., Chu, C.-S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0116 · Cited by 167
The Era of Cytotoxic CD4 T Cells
Cenerenti, M., Saillard, M., Romero, P., & Jandus, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867189 · Cited by 166
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Interferon-stimulated neutrophils as a predictor of immunotherapy response
Benguigui, M., Cooper, T. J., Kalkar, P., Schif-Zuck, S., Halaban, R., Bacchiocchi, A., Kamer, I., Deo, A., Manobla, B., Menachem, R., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.005 · Cited by 165
Veatch, J. R., Lee, S. M., Shasha, C., Singhi, N., Szeto, J. L., Moshiri, A. S., Kim, T. S., Smythe, K. S., Kong, P., Fitzgibbon, M., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.03.006 · Cited by 165
Johnson, D. B., Nixon, M. J., Wang, Y., Wang, D. Y., Castellanos, E., Estrada, M. V., Ericsson-Gonzalez, P. I., Cote, C. H., Salgado, R., Sanchez, V., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120360 · Cited by 163
Ramachandran, I., Lowther, D. E., Dryer-Minnerly, R., Wang, R., Fayngerts, S., Nunez, D., Betts, G. J., Bath, N. M., Tipping, A. J., Melchiori, L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0762-2 · Cited by 158
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 154
Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges
Lin, A., & Yan, W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02164 · Cited by 154
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Torrejon, D. Y., Abril-Rodriguez, G., Champhekar, A. S., Tsoi, J., Campbell, K. M., Kalbasi, A., Parisi, G., Zaretsky, J. M., Garcia-Diaz, A., Puig-Saus, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1409 · Cited by 146
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Qian, W., Zhao, M., Wang, R., & Li, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01161-8 · Cited by 144
Shim, J. H., Kim, H. S., Cha, H., Kim, S., Kim, T. M., Anagnostou, V., Choi, Y.-L., Jung, H. A., Sun, J.-M., Ahn, J. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.004 · Cited by 143
Li, B., Hao, G., Sun, B., Gu, Z., & Xu, Z. P. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909745 · Cited by 143
Considerations for designing preclinical cancer immune nanomedicine studies
Jiang, W., Wang, Y., Wargo, J. A., Lang, F. F., & Kim, B. Y. S. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-00817-9 · Cited by 142
Asleh, K., Negri, G. L., Miko, S. E. S., Colborne, S., Hughes, C. S., Wang, X. Q., Gao, D., Gilks, C. B., Chia, S., Nielsen, T. O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28524-0 · Cited by 135
Lin, W., Chen, L., Zhang, H., Qiu, X., Huang, Q., Wan, F., Le, Z., Geng, S., Zhang, A., Qiu, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35710-7 · Cited by 133
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Ziogas, D. C., Theocharopoulos, C., Koutouratsas, T., Haanen, J. B. A. G., & Gogas, H. J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102499 · Cited by 129
Nagasaki, J., Togashi, Y., Sugawara, T., Itami, M., Yamauchi, N., Yuda, J., Sugano, M., Ohara, Y., Minami, Y., Nakamae, H., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002098 · Cited by 128
Federico, A. D., Mosca, M., Pagani, R., Carloni, R., Frega, G., Giglio, A. D., Rizzo, A., Ricci, D., Tavolari, S., Marco, M. D., et al. (2022) · Cancers · doi:10.3390/cancers14102429 · Cited by 128
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 125
DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade
Chew, G.-L., Campbell, A. E., De Neef, E., Sutliff, N. A., Shadle, S. C., Tapscott, S. J., & Bradley, R. K. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.011 · Cited by 123
Wang, M. M., Coupland, S. E., Aittokallio, T. A., & Figueiredo, C. R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02361-4 · Cited by 122
Seremet, T., Jansen, Y., Planken, S., Njimi, H., Delaunoy, M., El Housni, H., Awada, G., Schwarze, J. K., Keyaerts, M., Everaert, H., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2051-8 · Cited by 119
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
Pérez-Guijarro, E., Yang, H. H., Araya, R. E., El Meskini, R., Michael, H. T., Vodnala, S. K., Marie, K. L., Smith, C., Chin, S., Lam, K. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0818-3 · Cited by 118
Sabbatino, F., Liguori, L., Polcaro, G., Salvato, I., Caramori, G., Salzano, F. A., Casolaro, V., Stellato, C., Col, J. D., & Pepe, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197295 · Cited by 115
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 114
Negrao, M. V., Lam, V. K., Reuben, A., Rubin, M. L., Landry, L. L., Roarty, E. B., Rinsurongkawong, W., Lewis, J., Roth, J. A., Swisher, S. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.008 · Cited by 112
Han, G., Deng, Q., Marques-Piubelli, M. L., Dai, E., Dang, M., Ma, M. C. J., Li, X., Yang, H., Henderson, J. M., Kudryashova, O. M., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0075 · Cited by 112
The role of biomarkers in personalized immunotherapy
Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00378-0 · Cited by 111
Arrieta, V. A., Gould, A., Kim, K.-S., Habashy, K. J., Dmello, C., Vázquez-Cervantes, G. I., Palacín-Aliana, I., McManus, G., Amidei, C., Gomez, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48326-w · Cited by 107
Pech, M. F., Fong, L. E., Villalta, J. E., Chan, L. J., Kharbanda, S., O’Brien, J. J., McAllister, F. E., Firestone, A. J., Jan, C. H., & Settleman, J. E. (2019) · eLife · doi:10.7554/elife.47362 · Cited by 104
Trials and tribulations of pancreatic cancer immunotherapy
Principe, D. R., Korc, M., Kamath, S. D., Munshi, H. G., & Rana, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.01.031 · Cited by 100
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 98
Origin and Therapies of Osteosarcoma
Moukengué, B., Lallier, M., Marchandet, L., Baud’huin, M., Verrecchia, F., Ory, B., & Lamoureux, F. (2022) · Cancers · doi:10.3390/cancers14143503 · Cited by 98
Liquid biopsy: one cell at a time
Lim, S. B., Lee, W. D., Vasudevan, J., Lim, W., & Lim, C. T. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0095-0 · Cited by 97
Dóra, D., Rivard, C. J., Yu, H., Bunn, P. A., Suda, K., Ren, S., Pickard, S. L., László, V., Harkó, T., Megyesfalvi, Z., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12741 · Cited by 97
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer
Demel, U. M., Böger, M., Yousefian, S., Grunert, C., Zhang, L., Hotz, P. W., Gottschlich, A., Köse, H., Isaakidis, K., Vonficht, D., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152383 · Cited by 97
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Lauss, M., Phung, B., Borch, T. H., Harbst, K., Kaminska, K. K., Ebbesson, A., Hedenfalk, I. A., Yuan, J., Nielsen, K., Ingvar, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47425-y · Cited by 96
STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity
Falahat, R., Perez-Villarroel, P., Mailloux, A. W., Zhu, G., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0229 · Cited by 95
Metadata
- Authors
- Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., Weirather, J. L., Wolchok, J. D., Postow, M. A., Pavlick, A. C., Chesney, J., & Hodi, F. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Bristol-Myers Squibb (United States) (US)
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- NYU Langone Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Louisville (US)
- Corresponding author
- Rodig, Scott J.
- Hodi, F. Stephen
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-07-18
- Volume
- 10
- Issue
- 450
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2883970691
- Cited by
- 579
- References
- 59
- Citations by year
- 2026: 38 · 2025: 48 · 2024: 75 · 2023: 101 · 2022: 94 · 2021: 79 · 2020: 76 · 2019: 55 · 2018: 12
- FWCI
- 20.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Funded by Bristol-Myers Squibb (N/A)
- NIH/NCI Cancer Center (P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- metastatic melanoma, MHC class I expression, MHC class II expression, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint inhibitors, interferon-gamma, innate immunity, tumor antigen presentation, antitumor immunity, predictive biomarkers
- MeSH terms
- HLA Antigens, Humans, Immunity, Innate, Immunotherapy, Melanoma, Transcription, Genetic, Gene Expression Regulation, Neoplastic, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.